Proactivplus Pore Clearing Treatment

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the management of acne.

There are no teratogenic or nonteratogenic effects associated with this medication.

Dosage and Administration

Healthcare professionals should initiate treatment with a sensitivity test for new users by applying the product sparingly to one or two small affected areas for the first three days. If no discomfort is experienced, the following dosing regimen may be implemented.

Prior to application, the skin must be cleaned thoroughly. The product should then be applied to the entire affected area in a thin layer. The recommended frequency of application is one to three times daily. It is advisable to start with one application per day to minimize the risk of excessive drying of the skin. Based on the patient's response, the frequency may be gradually increased to two or three times daily, or as directed by a physician.

In cases where bothersome dryness or peeling occurs, the application frequency should be reduced to once daily or every other day to alleviate these symptoms.

Contraindications

There are no specific contraindications listed for this product. However, it is advised to avoid unnecessary sun exposure and to use a sunscreen to minimize potential skin reactions. Additionally, contact with the eyes should be avoided; in the event of contact, it is recommended to rinse the eyes thoroughly with water.

Warnings and Precautions

For external use only.

Skin irritation and dryness may be exacerbated when used concurrently with other topical acne medications. It is advised that only one topical acne medication be utilized at a time to minimize the risk of irritation. Healthcare professionals should counsel patients to avoid unnecessary sun exposure and to apply a broad-spectrum sunscreen to protect the skin.

Contact with the eyes should be strictly avoided. In the event of accidental contact, it is imperative to rinse the eyes thoroughly with water to mitigate potential irritation.

In cases of ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Patients are encouraged to communicate any adverse effects or concerns to their healthcare provider promptly.

Side Effects

For external use only. No specific adverse reactions have been reported in clinical trials or postmarketing experiences. Patients should be advised to adhere strictly to the recommended usage guidelines to minimize the risk of adverse effects.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Proactivplus Pore Clearing Treatment (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information regarding the use of Proactivplus Pore Clearing Treatment in geriatric patients. The prescribing information does not provide details on dosage adjustments, safety concerns, or special precautions that may be necessary for elderly patients. Therefore, healthcare providers should exercise caution and consider individual patient factors when prescribing this treatment to geriatric patients, as the absence of specific data necessitates careful monitoring and assessment of treatment efficacy and safety in this population.

Pregnancy

The product has not been evaluated for use during pregnancy. There are no specific warnings or contraindications associated with the use of this product in pregnant patients. Additionally, the prescribing information does not provide any dosage modifications for individuals who are pregnant. Furthermore, no special precautions regarding the use of this product during pregnancy are indicated. Healthcare professionals should consider the lack of data when prescribing this product to women of childbearing potential and weigh the potential benefits against any unknown risks.

Lactation

There are no specific warnings or recommendations regarding the use of this product by lactating mothers. Additionally, there are no statements concerning the potential for excretion in breast milk or any associated risks to breastfed infants during the use of this product.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary significantly depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, including airway management, oxygen supplementation, and intravenous fluids.

If the specific agent involved in the overdose is known, appropriate antidotes or specific treatments should be administered as indicated. Continuous monitoring of the patient’s condition is crucial, and healthcare providers should be prepared to manage complications that may arise during the course of treatment.

In all cases of suspected overdose, it is advisable to contact a poison control center or consult relevant clinical guidelines for further management recommendations.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed.

Patients should be informed that the use of this medication in conjunction with other topical acne treatments may increase the likelihood of skin irritation and dryness. It is recommended that patients use only one topical acne medication at a time to minimize the risk of irritation.

Additionally, healthcare providers should counsel patients on the importance of avoiding unnecessary sun exposure while using this medication. Patients should be encouraged to apply a broad-spectrum sunscreen to protect their skin.

Providers must also emphasize the need to avoid contact with the eyes. In the event of accidental eye contact, patients should be instructed to rinse their eyes thoroughly with water to mitigate any potential irritation.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a controlled temperature range of 20 to 25°C (68 to 77°F) to maintain its integrity and efficacy. Proper storage conditions must be adhered to, ensuring that the product is kept within the specified temperature limits.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Proactivplus Pore Clearing Treatment, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)